Literature DB >> 23974048

Etazolate rescues behavioral deficits in chronic unpredictable mild stress model: modulation of hypothalamic-pituitary-adrenal axis activity and brain-derived neurotrophic factor level.

Ankur Jindal1, Radhakrishnan Mahesh, Shvetank Bhatt.   

Abstract

Preliminary study in our laboratory showed that etazolate produced antidepressant- and anxiolytic-like effects in rodent models, however, the ability of etazolate to produce antidepressant- and anxiolytic-like effects and underlying mechanism(s) in chronic unpredictable mild stress (CUMS) model have not been adequately addressed. This study was aimed to investigate the beneficial effects of etazolate on CUMS-induced behavioral deficits (depression- and anxiety-like behaviors). In addition, the possible underlying mechanism(s) of etazolate in CUMS model was also investigated by measuring serum corticosterone (CORT) and brain-derived neurotrophic factor (BDNF) levels. Mice were subjected to a battery of stressors for 28 days. Etazolate (0.5 and 1 mg/kg, p.o.) and fluoxetine (20mg/kg, p.o.) were administered during the last 21 days (8-28th) of the CUMS paradigm. The results showed that 4-weeks CUMS produces significant depression-like behavior in tail suspension test (TST) and partial anxiety-like behavior in elevated plus maze (EPM) and open field test (OFT). Stressed mice have also shown a significant high serum CORT and low BDNF level. Chronic treatment with etazolate (0.5 and 1mg/kg., p.o.) and fluoxetine (20mg/kg., p.o.) produced significant antidepressant-like behavior in TST (decreased duration of immobility), whereas, partial anxiolytic-like behavior in EPM (increased percentage of open arm entries) and OFT (increased % central ambulation score, total ambulation score and time spent in center zone). In addition, etazolate and fluoxetine treatment significantly (p<0.05) increased the BDNF level and inhibited the hypothalamic-pituitary-adrenocortical (HPA) axis hyperactivity, as evidenced by low serum CORT level in stressed mice. In addition, etazolate and fluoxetine also showed significant antidepressant- and anxiolytic-like effects in normal control mice. In this study no significant changes were observed in locomotor activity in actophotometer test. Moreover, we did not find any effect of etazolate and fluoxetine on CORT and BDNF levels in normal control mice. In conclusion, the results of the present study suggested compelling evidences that etazolate has more marked effect on depression-like behavior in mice, which is atleast in part may be related to their modulating effects on the HPA axis and BDNF level.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BDNF; CUMS; Depression; Etazolate; HPA axis

Mesh:

Substances:

Year:  2013        PMID: 23974048     DOI: 10.1016/j.neuint.2013.08.005

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  15 in total

1.  Honokiol Exerts Antidepressant Effects in Rats Exposed to Chronic Unpredictable Mild Stress by Regulating Brain Derived Neurotrophic Factor Level and Hypothalamus-Pituitary-Adrenal Axis Activity.

Authors:  Canmao Wang; Danna Gan; Jingang Wu; Minhui Liao; Xinghuan Liao; Weipeng Ai
Journal:  Neurochem Res       Date:  2018-05-31       Impact factor: 3.996

2.  Etazolate, a phosphodiesterase-4 enzyme inhibitor produces antidepressant-like effects by blocking the behavioral, biochemical, neurobiological deficits and histological abnormalities in hippocampus region caused by olfactory bulbectomy.

Authors:  Ankur Jindal; Radhakrishnan Mahesh; Shvetank Bhatt
Journal:  Psychopharmacology (Berl)       Date:  2014-08-15       Impact factor: 4.530

3.  Antidepressant-like Effect of Bacopaside I in Mice Exposed to Chronic Unpredictable Mild Stress by Modulating the Hypothalamic-Pituitary-Adrenal Axis Function and Activating BDNF Signaling Pathway.

Authors:  Xianpeng Zu; Mingjian Zhang; Wencai Li; Haisheng Xie; Zhang Lin; Niao Yang; Xinru Liu; Weidong Zhang
Journal:  Neurochem Res       Date:  2017-07-31       Impact factor: 3.996

4.  Ursolic acid abrogates depressive-like behavior and hippocampal pro-apoptotic imbalance induced by chronic unpredictable stress.

Authors:  André R S Colla; Francis L Pazini; Vicente Lieberknecht; Anderson Camargo; Ana Lúcia S Rodrigues
Journal:  Metab Brain Dis       Date:  2021-01-04       Impact factor: 3.584

5.  Viral-mediated overexpression of the Myelin Transcription Factor 1 (MyT1) in the dentate gyrus attenuates anxiety- and ethanol-related behaviors in rats.

Authors:  Amine Bahi; Jean-Luc Dreyer
Journal:  Psychopharmacology (Berl)       Date:  2017-03-16       Impact factor: 4.530

6.  Antidepressant-like effects of the phosphodiesterase-4 inhibitor etazolate and phosphodiesterase-5 inhibitor sildenafil via cyclic AMP or cyclic GMP signaling in mice.

Authors:  Chuang Wang; Jianrui Zhang; Yang Lu; Peipei Lin; Tonghe Pan; Xin Zhao; Aiming Liu; Qinwen Wang; Wenhua Zhou; Han-Ting Zhang
Journal:  Metab Brain Dis       Date:  2014-04-05       Impact factor: 3.584

7.  Long-term inflammatory pain does not impact exploratory behavior and stress coping strategies in mice.

Authors:  Dominika J Burek; Nicolas Massaly; Michelle Doering; Azra Zec; Jordan Gaelen; Jose A Morón
Journal:  Pain       Date:  2021-06-01       Impact factor: 7.926

8.  Dysregulation of the hypothalamus-pituitary-adrenal axis predicts some aspects of the behavioral response to chronic fluoxetine: association with hippocampal cell proliferation.

Authors:  Wahid Khemissi; Rai Khalid Farooq; Anne-Marie Le Guisquet; Mohsen Sakly; Catherine Belzung
Journal:  Front Behav Neurosci       Date:  2014-09-30       Impact factor: 3.558

9.  Changes in proinflammatory cytokines and white matter in chronically stressed rats.

Authors:  Ping Yang; Zhenyong Gao; Handi Zhang; Zeman Fang; Cairu Wu; Haiyun Xu; Qing-Jun Huang
Journal:  Neuropsychiatr Dis Treat       Date:  2015-03-06       Impact factor: 2.570

10.  Antidepressant-like effects of cordycepin in a mice model of chronic unpredictable mild stress.

Authors:  Zhang Tianzhu; Yang Shihai; Du Juan
Journal:  Evid Based Complement Alternat Med       Date:  2014-12-23       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.